Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2025 05:42 ET | Source: Curium

Curium and NRG PALLAS extend collaboration in the supply of essential medical isotope to hospitals

PETTEN, The Netherlands, May 21, 2025 (GLOBE NEWSWIRE) -- NRG PALLAS and Curium have extended their collaboration to produce molybdenum-99 through a new multi-year agreement. Molybdenum-99, which...
January 28, 2025 04:24 ET | Source: Curium

Curium Further Expands European Availability of PYLCLARI – an Innovative 18F-PSMA PET Radiopharmaceutical Indicated in Patients with Prostate Cancer

Curium announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with prostate cancer.
May 06, 2024 04:25 ET | Source: Curium

Curium: Erste Kommerzielle Dosen von PYLCLARI® in Deutschland Verfügbar - Ein Innovativer 18f-PSMA PET Tracer für Patienten Mit Prostatakrebs

PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, ein weltweit führendes Unternehmen der Nuklearmedizin, gab heute bekannt, dass in München und Nürnberg die ersten kommerziellen Dosen von PYLCLARI®...
May 06, 2024 04:25 ET | Source: Curium

Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Curium announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI® have been delivered.
February 06, 2024 05:23 ET | Source: Curium

Curium Announces Ioflupane I 123 Injection Availability for Friday Patient Use

Exciting news from Curium! Starting April 5, 2024, our Ioflupane I 123 Injection will be delivered Monday through Friday.
May 26, 2023 03:42 ET | Source: Curium

Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific Antigen (PSA) Levels After Primary Treatment With Curative Intent

If approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known as [18F]-DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional...
May 23, 2023 12:57 ET | Source: Curium

Curium Announces Last Patient Enrolled in Their Phase 1/2 SOLAR Clinical Trial Imaging Men with Histologically-Proven Metastatic Prostate Cancer Using Copper Cu 64 PSMA I&T.

PARIS, May 23, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has completed enrollment in its USA-led SOLAR Phase 1/2 study evaluating the safety,...
March 02, 2023 07:44 ET | Source: Curium

Innovation and Growing Demand for Nuclear Medicine Drives Curium Expansion and 10-Year Commitment to St. Louis, MO

Renaissance in nuclear medicine to attract top St. Louis talentNorth America Headquarters to call Westport Plaza home for the next 10 yearsOver 100 new jobs in the next 3 years ST. LOUIS, March 02,...
December 21, 2022 10:26 ET | Source: Curium

Curium’s 14 Million Patients to Benefit From Regular Supply of Mo-99 and Tc-99

PARIS, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today that with the successful restarting of the BR2 research reactor in Belgium on 20...
January 25, 2022 00:00 ET | Source: Curium

Curium to become major player in the supply on non carrier added Lu-177

London, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Today Curium has announced a technology license agreement granting access to ECZACIBAŞI MONROL NÜKLEER ÜRÜNLER SANAYİ VE TİCARET A.Ş non carrier added...

Next Page keyboard_arrow_right